1 |
Kumagai, K., I. Ohno, S. Okada, Y. Ohkawara, S.K. uzuki, T. Shinya, H. Nagase, K. Iwata, and S.K. hirato. 1999. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J. Immunol. 162, 4212-4219
PUBMED
|
2 |
Lukacs, N.W. 2000. Migration of helper T-lymphocyte subsets into inflamed tissues. J. Allergy Clin. Immunol. 106, 264-269
DOI
ScienceOn
|
3 |
Okada, S., H. Kita, T.J. George, G.J. Gleich, and K.M. Leiferman. 1997. Migration of eosinophil through basement membrane components in vitro:role of matrix metalloproteinase-9. Am. J. Respir. Cell Mol. Biol. 17, 519-528
DOI
PUBMED
ScienceOn
|
4 |
Van Eerdewegh, P., R.D. Little, and J. Dupuis. 2002. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418, 426-430
DOI
ScienceOn
|
5 |
Warner, J.A., P. Julius, W. Luttmann, and C. Kroegel. 1997. Matrix metalloproteinases in bronchoalveolar lavage fluid following antigen challenge. Int. Arch. Allergy Immunol. 113, 318-320
DOI
ScienceOn
|
6 |
Kelly, E.A. and N.N. Jarjour. 2003. Role of matrix metalloproteinases in asthma. Current Opinion in Pulmonary Medicine. 9, 28-33
DOI
PUBMED
ScienceOn
|
7 |
Gingras, D., A. Renaud, N. Mousseau, E. Beaulieu, Z. Kachra, and R. Beliveau. 2001. Matrix proteinase Inhibition by -941, a multifunctional antiangiogenic compound. Anticancer Res. 21, 145-155
PUBMED
|
8 |
Mautino, G., N. Oliver, P. chanez, J. Bousquet, and F. Capony. 1997. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophgages of asthmatics. Am. J. Respir. Cell Mol. Biol. 17, 583-591
DOI
PUBMED
ScienceOn
|
9 |
Beliveau, R., D. Gingras, E.A. Kruger, S. Lamy, P. Sirois, B. Simard, M.G. Sirois, L. Tranqui, F. Baffert, E. Beaulieu, V. Dimitriadou, M.C. Pepin, F. Courjal, I. Ricard, P. Poyet, P. Falardeau, W.D. Figg, and E. Dupont. 2002. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin. Cancer Res. 8, 1242-1250
PUBMED
|
10 |
Falardeau, P., P. Champagne, P. Poyet, C. Hariton, and E, Dupont. 2001. -941 (Neovastat), a naturally occurring multifunctional anti-angiogenic product in Phase clinical trials. Semin. Oncol. 28, 620-625
|
11 |
Adcock, I.M. 1996. Steroid resistance in asthma. Molecular mechanisms. Am. J. Respir. Crit. Care Med. 154, S58-61
DOI
|
12 |
Gingras, D., G. Batist, and R. Beliveau. 2001. -941 (Neovastat): A novel multifunctional antiangiogenic compound. Expert Rev. Anticancer Ther. 1, 341-347
DOI
PUBMED
ScienceOn
|
13 |
Delcaux, C., C. Delacourt, M.P. d'Ortho, V. Boyer, C. Lafuma, and A. Harf. 1996. Role of gelatinase B and elastase in human polymorphonuclear neutrohil migration across basement membrane. Am. J. Respir. Cell Mol. Biol. 14, 288-295
DOI
PUBMED
ScienceOn
|
14 |
Boivin, D., S. Gendron, Beaulieu, D. Gingras, and R. Beliveau. 2002. The Antiangiogenic Agent Neovastat (-941) Induces Endothelial Cell Apoptosis. Molecular Cancer Therapeutics. 1, 795-802
PUBMED
|
15 |
Stricklin, G. and H. Welgus. 1983. Human skin fibroblasts collagenase inhibitor : purification and biochemical characterization. J. Biol. Chem. 258, 12252-12258
PUBMED
|
16 |
Lee, K.S., S.M. Jin, H.J. Kim, and Y.C. Lee. 2003. Matrix metalloproteinase inhibitor regulates inflammatory cell migration by reducing ICAM-1 and VCAM-1 expression in a murine model of toluene diisocyanate-induced asthma. J. Allergy Clin. Immunol. 111, 1278-1284
DOI
ScienceOn
|
17 |
Castronovo, V., V. Dimitriadou, P. Savard, M. Riviere, and E. Dupont. 1999. Cartilage as a source of natural inhibitors of angiogenesis. Antiangiogenic Agents in Cancer Therapy, p. 175-83. Humana Press, Totowa, New Jersey
|
18 |
Dunnill, M.S. 1960. The pathology of asthma with special reference to changes in the bronchial mucosa. J. Clin. Patho. 13, 27-33
DOI
PUBMED
|
19 |
Jonathan, P.A. and T.H. Lee. 1992. The pathobiology of bronchial asthma. Adv. Immunol. 51, 323-329
DOI
PUBMED
|
20 |
Lee, Y.C., C.H. Song, H.B. Lee, J.L. Oh, Y.K. Rhee, H.S. Park, and G.Y. Koh. 2001. A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor. J. Allergy Clin. Immunol. 108, 1021-1026
DOI
ScienceOn
|
21 |
Stetler-Stevenson, W.G., H.C. Krutzsch, and L.A. Liotta. 1989. Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase family. J. Biol Chem. 264, 17374-17378
PUBMED
|
22 |
Nagase, H. 1997. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378, 151-160
PUBMED
|
23 |
Cho, J.Y., M. Miller, K.J. Baek, G. W. Han, J. Nayar, M. Rodriguez, S.Y. Lee, K. McElwain, S. McElwain, E. Raz, and D.H. Broide. 2004. Immunostimulatory DNA Inhibits Transforming Growth Factor- Expression and Airway Remodeling. Am. J. Respir. Cell Mol. Biol. 30, 651-661
DOI
ScienceOn
|
24 |
Yang, H., S. Han, H. Kim, Y.M. Choi, K.J. Hwang, H.C. Kwon, S.K. Kim, and D.J. Cho. 2002. Expression of integrines, cyclooxygenases and matrix metalloproteinases in threedimensional human endometrial cell culture system. Exp. Mol. Med. 34, 75-82
DOI
PUBMED
ScienceOn
|
25 |
Sternlicht, M.D. and Z. Werb. 2001. How Matrix Metalloproteinases Regulate Cell Behavior. Ann. Rev. Cell Dev. Biol. 17, 463-516
DOI
ScienceOn
|
26 |
Li, X. and J.W. Wilson. 1997. Increased vascularity of the bronchial mucosa in mild asthma. Am. J. Respir. Crit. Card. Med. 156, 229-233
DOI
ScienceOn
|
27 |
Leppert, D., E. Waubant, R. Galardy, N.W. Bunnett, and S.L. Hauser. 1995. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154, 4379-4389
PUBMED
|